Increased breast cancer risk in in vitro fertilisation treated women with a multiple pregnancy: A new hypothesis based on historical in vitro fertilisation treatment data

2015 ◽  
Vol 51 (1) ◽  
pp. 112-120 ◽  
Author(s):  
I.M. Krul ◽  
E. Groeneveld ◽  
M. Spaan ◽  
A.W. van den Belt-Dusebout ◽  
T.M. Mooij ◽  
...  

2015 ◽  
Vol 17 (1) ◽  
Author(s):  
Heleen K Bronsveld ◽  
Bas ter Braak ◽  
Øystein Karlstad ◽  
Peter Vestergaard ◽  
Jakob Starup-Linde ◽  
...  


JAMA ◽  
2016 ◽  
Vol 316 (16) ◽  
pp. 1713
Author(s):  
Alexandra W. van den Belt-Dusebout ◽  
Flora E. van Leeuwen ◽  
Curt W. Burger


2003 ◽  
Vol 9 (1) ◽  
pp. 36-38
Author(s):  
Harald Seeger ◽  
Diethelm Wallwiener ◽  
Alfred O Mueck

Objective To investigate in vitro the influence of the three most used progestogens in continuous combined HRT on cell proliferation of the human breast cancer cell line MCF-7. Study design Progesterone (P), medroxyprogesterone acetate (MPA) and norethisterone (NET) were investigated in the range of 0.01 nM to 10 μM alone and in combination with 10 nM oestradiol. Cell proliferation was measured after seven days using the ATP-chemosensitivity test. Results P alone reduced cell proliferation by 20 and 40% at 10−7 and 10−5 M. MPA and NET displayed a significant inhibition of cell proliferation between 20 and 25% for MPA and 23 and 41% for NET over the whole concentration range tested. The effect was greatest at 10−7 M for MPA and at 10−9 M for NET. In combination with oestradiol, P still significantly reduced cell proliferation, the values being between 12 and 61%. For MPA too an inhibitory effect between 20 and 40% was found, whereas for NET the values were between 23 and 38%. Conclusions Our in vitro results indicate that the influence on breast cancer risk using HRT in postmenopausal women may depend on the type of progestogen used as well as on the regimen applied. However, the inhibitory in vitro net effect of the progestogens at clinically relevant dosages is rather minimal and it remains uncertain as to whether progestogens generally may reduce breast cancer risk in long-term treatment. Further clinical trials are urgently required to determine the appropriate choice - if any - of progestogen to complement HRT.



JAMA ◽  
2016 ◽  
Vol 316 (16) ◽  
pp. 1713
Author(s):  
Federica Tomao ◽  
Anselmo Papa ◽  
Silverio Tomao


2013 ◽  
Vol 1 (1) ◽  
Author(s):  
A Koumousidis ◽  
M Varras ◽  
C Sofoudis ◽  
N Salakos


2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Sha Diao ◽  
Xueyao Wu ◽  
Xiaofan Zhang ◽  
Yu Hao ◽  
Bin Xu ◽  
...  

AbstractThere is strong evidence to suggest that obesity-related proteins play a key role in pathways that are related to breast cancer. In this study, we aimed to establish a robust obesity-related protein score (ORPS) that could be used to assess breast cancer risk. Based on evidence from high-quality systematic reviews and population studies, we selected nine such proteins that are stable in vitro, and measured their circulating concentrations by ELISA in a case–control study conducted in Chengdu, Sichuan, China, with 279 breast cancer cases and 260 healthy controls. Two obesity-related protein scores (ORPS) were calculated using a three-step method, with linear-weighted summation, and the one with a larger area under the curve was chosen for further evaluation. As a result, ORPS (PS5pre or PS4post) was positively correlated with breast cancer risk (premenopausal: OR≤63 VS >63 3.696, 95% CI 2.025–6.747; postmenopausal: OR≤38 VS >38 7.100, 95% CI 3.134–16.084), and represented a better risk predictor among obese women compared to non-obese in pre- and postmenopausal women. Among different molecular subtypes, ORPS was positively correlated with Luminal breast cancer, with additionally positive association with triple-negative breast cancer in premenopausal women. The ORPS might be a potential marker of breast cancer risk among Chinese women.



2015 ◽  
Vol 22 (1) ◽  
pp. 9-44 ◽  
Author(s):  
Katarína Kráľová ◽  
Josef Jampílek

Abstract Breast cancer is the most frequent cancer in women. It is believed that among the causes of breast cancer, hereditary factors account for only 5-10% of risk and the environmental exposures to environmental contaminants account for an additional 30-50% of risk. This paper summarizes findings related to the risk of breast cancer due to exposure to following environmental contaminants: polycyclic aromatic hydrocarbons, polychlorinated biphenyls and dioxins, organochlorine pesticides, organophosphorous pesticides, bisphenol A, phthalates, parabens, organic solvents, atmospheric pollutants, alkylphenols, metals, ionizing radiation, electromagnetic field and light pollution. Results obtained in in vitro experiments with breast cancer cell lines and in vivo with model rodents as well as in population based case-control studies are presented and the mode of action of individual environmental contaminants on mammary gland is discussed. Attention is also devoted to the effects of the timing of exposure to environmental contaminants (mainly exposition during development of the mammary gland) on breast cancer risk. Outcomes of professional exposure to some environmental contaminants on breast cancer risk are analysed as well



Sign in / Sign up

Export Citation Format

Share Document